What's in APOGEPHA Arzneimittel GmbH's pipeline?

APOGEPHA Arzneimittel GmbH has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with APOGEPHA Arzneimittel GmbH's portfolio?

Top competitors by shared drug class: Alcon Labs Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/apogepha-arzneimittel-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

APOGEPHA Arzneimittel GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APOGEPHA Arzneimittel GmbH pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
propiverine hydrochloride	propiverine hydrochloride	marketed
Mictonetten 5 mg, coated tablet	Mictonetten 5 mg, coated tablet	phase 3	Antimuscarinic agent	M3 muscarinic receptor	Urology

Therapeutic area mix

Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alcon Labs Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for APOGEPHA Arzneimittel GmbH:

Cite this brief

Drug Landscape (2026). APOGEPHA Arzneimittel GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apogepha-arzneimittel-gmbh. Accessed 2026-05-17.